Scarica l'app Stockscreener
32.99
2.17%
0.70
Dopo l'orario di chiusura:
32.99
Precedente Chiudi:
$32.29
Aprire:
$31
Volume 24 ore:
601.67K
Relative Volume:
0.98
Capitalizzazione di mercato:
$1.57B
Reddito:
-
Utile/perdita netta:
$-86.97M
Rapporto P/E:
-13.64
EPS:
-2.4189
Flusso di cassa netto:
$-81.88M
1 W Prestazione:
+16.61%
1M Prestazione:
+0.06%
6M Prestazione:
+96.96%
1 anno Prestazione:
+373.31%
Intervallo 1D:
$30.87
$33.70
Intervallo di 1 settimana:
$26.14
$33.70
Portata 52W:
$4.8069
$44.89
Mbx Biosciences Inc Stock (MBX) Company Profile
Nome
Mbx Biosciences Inc
Settore
Industria
Telefono
(317) 989-3100
Indirizzo
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
32.99 | 1.57B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-12-04 | Iniziato | Goldman | Sell |
| 2025-11-04 | Iniziato | TD Cowen | Buy |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-08-15 | Ripresa | Jefferies | Buy |
| 2025-08-05 | Iniziato | Mizuho | Outperform |
| 2025-07-16 | Iniziato | Oppenheimer | Outperform |
| 2025-04-10 | Iniziato | Citizens JMP | Mkt Outperform |
| 2024-10-08 | Iniziato | Guggenheim | Buy |
| 2024-10-08 | Iniziato | JP Morgan | Overweight |
| 2024-10-08 | Iniziato | Jefferies | Buy |
| 2024-10-08 | Iniziato | Stifel | Buy |
Mostra tutto
Mbx Biosciences Inc Borsa (MBX) Ultime notizie
Does MBX (MBX) Options-Driven Breakout Reveal Deeper Shifts In Its Investment Narrative? - Yahoo! Finance Canada
MBX Biosciences (MBX) Is Up 16.6% After Analyst Initiation And Leadership Award News Has The Bull Case Changed? - Sahm
MBX Biosciences Approves Equity-Based Inducement Grant for New Employee Under Nasdaq Rule - geneonline.com
MBX Biosciences Reports Inducement Grant - National Today
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New MBX business chief gets 130,000 stock options at $32.29 - Stock Titan
Lifesci Capital Weighs in on MBX Biosciences Q1 Earnings - MarketBeat
MBX Biosciences (NASDAQ:MBX) Upgraded at Lifesci Capital - MarketBeat
MBX Biosciences (NASDAQ:MBX) Shares Up 8.5%What's Next? - MarketBeat
MBX Biosciences, Inc. (NASDAQ:MBX) Sees Large Increase in Short Interest - MarketBeat
MBX PE Ratio & Valuation, Is MBX Overvalued - Intellectia AI
221,672 Shares in MBX Biosciences, Inc. $MBX Acquired by Goelzer Investment Management Inc. - MarketBeat
Assessing MBX Biosciences (MBX) Valuation After CEO Share Purchase And Phase 3 Hypoparathyroidism Plans - Sahm
MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know - Yahoo Finance
Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? - msn.com
MBX Biosciences, Inc. (NASDAQ:MBX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
MBX (NASDAQ: MBX) affiliate files sale notice for 1,061 vested shares - Stock Titan
MBX Biosciences (MBX) Is Down 6.5% After Wider Losses And New Shelf Filings Has The Bull Case Changed? - simplywall.st
Hudson Bay Capital Management LP Purchases New Stake in MBX Biosciences, Inc. $MBX - MarketBeat
Aug Intraday: Can MBX Biosciences Inc keep up with sector leaders2026 Risk Factors & AI Powered Trade Plan Recommendations - baoquankhu1.vn
MBX Biosciences Advances Avail Phase 2 Trial in Hypoparathyroidism: What Investors Should Watch - TipRanks
Top MBX Biosciences (MBX) Competitors 2026 - MarketBeat
MBX Biosciences (MBX) CFO John Smither files initial Form 3 - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
MBX Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MBX Biosciences Chief Makes Bold Insider Move With Major Stock Buy - TipRanks
Company (NASDAQ: MBX) Form 144 — 10,000-share sale notice via Fidelity - Stock Titan
MBX Biosciences (NASDAQ:MBX) Shares Gap Up After Insider Buying Activity - MarketBeat
A Look At MBX Biosciences (MBX) Valuation After Recent Share Price Pullback - simplywall.st
Hawryluk P. Kent buys MBX Biosciences shares worth $525,662 By Investing.com - Investing.com India
Hawryluk P. Kent buys MBX Biosciences shares worth $525,662 - Investing.com
MBX Biosciences (NASDAQ:MBX) CEO Buys $525,585.00 in Stock - MarketBeat
MBX Biosciences (MBX) CEO adds 18,500 shares via trust purchase - Stock Titan
MBX Phase 3 Plans And New CBO Sharpen Rare Disease Focus - Yahoo Finance
Baker BROS. Advisors LP Takes $4.86 Million Position in MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences completes FDA meeting for Phase 3 trial design - Investing.com Nigeria
Ghisallo Capital Management LLC Takes $669,000 Position in MBX Biosciences, Inc. $MBX - MarketBeat
Wall Street Analysts See a 142% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? - MSN
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and REPRO-MED Systems (KRMD) - The Globe and Mail
MBX Biosciences Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Citizens reiterates Market Outperform on MBX Biosciences stock - Investing.com Nigeria
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights - Sahm
Cowen Maintains Buy on MBX Biosciences, Inc. Common Stock (MBX) Mar 2026 - Meyka
Decoding MBX Biosciences Inc (MBX): A Strategic SWOT Insight - GuruFocus
Truist reiterates Buy on MBX Biosciences stock, $50 target - Investing.com South Africa
Truist reiterates Buy on MBX Biosciences stock, $50 target By Investing.com - Investing.com India
MBX Biosciences (NASDAQ: MBX) files $250M ATM sales agreement with Jefferies - Stock Titan
Stifel reiterates Buy rating on MBX Biosciences stock, $50 target - Investing.com UK
Stifel reiterates Buy rating on MBX Biosciences stock, $50 target By Investing.com - Investing.com Australia
TD Cowen reiterates Buy on MBX Biosciences stock ahead of Phase III By Investing.com - Investing.com Australia
TD Cowen reiterates Buy on MBX Biosciences stock ahead of Phase III - Investing.com India
Mbx Biosciences Inc Azioni (MBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):